Consistently, clinical trials are currently underway in glioblastoma multiforme (NCT04477200, NCT05236036) to evaluate the combination of mycophenolate mofetil (MMF, a prodrug form of the IMPDH2 inhibitor MPA, possessing better bioavailability) with temozolomide and/or radiation50,51. The gene discussed is IMPDH2; the disease is glioblastoma.